Browse our HRAS Proteins (HRAS)

Full name:
V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog Proteins (HRAS)
On www.antibodies-online.com are 19 V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Proteins from 8 different suppliers available. Additionally we are shipping HRAS Antibodies (143) and HRAS Kits (14) and many more products for this protein. A total of 187 HRAS products are currently listed.
Synonyms:
AI929937, C-BAS/HAS, c-H-ras, c-Ha-ras, C-HA-RAS1, c-rasHa, CTLO, H-ras, H-RASIDX, Ha-ras, HAMSV, Harvey-ras, hras, Hras-1, HRAS1, K-ras, Ki-ras, Kras-2, Kras2, N-RAS, p21B, ras, RASH1, zgc:110250
list all proteins Gene Name GeneID UniProt
HRAS 3265 P01112
HRAS 293621 P20171
HRAS 15461 Q61411

Show all synonyms

HRAS Proteins (HRAS) by Origin

Select your origin of interest

Top referenced HRAS Proteins

  1. Human HRAS Protein expressed in Baculovirus infected Insect Cells - ABIN2005011 : Sekiya, Fushimi, Hori, Hirohashi, Nishimura, Sugimura: Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient. in Proceedings of the National Academy of Sciences of the United States of America 1984 (PubMed)
    Show all 6 references for 2005011

  2. Human HRAS Protein expressed in Escherichia coli (E. coli) - ABIN666969 : Ayllón, Rebollo: Ras-induced cellular events (review). in Molecular membrane biology 2000 (PubMed)
    Show all 2 references for 666969

More Proteins for HRAS Interaction Partners

Cow (Bovine) V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. Data demonstrate that H-Ras activation is important in the activation of the specific signaling events leading to the accelerated retinal capillary cell apoptosis in hyperglycemic conditions.

  2. Activation of H-Ras and its downstream signaling pathway in the retina and its vasculature could be under the control of superoxide, and H-Ras activation in diabetes can be prevented by inhibiting superoxide accumulation.

  3. Thrombospondin 1 (show THBS1 Proteins), fibronectin (show FN1 Proteins), and vitronectin (show VTN Proteins) are differentially dependent upon RAS, ERK1/2, and p38 (show MAPK14 Proteins) for induction of vascular smooth muscle cell chemotaxis.

Zebrafish V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish

Human V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. Data suggest that isoform-specific sequences in the allosteric lobes of HRAS, KRAS, and NRAS (show NRAS Proteins) have an impact on biocatalysis (kinetics of GTP (show AK3 Proteins) hydrolysis) and interaction with c-Raf (show RAF1 Proteins) kinase, which must be due to allosteric effects on dynamics and conformational states, given the identical active sites of these isoenzymes.

  2. Data suggest HRas activates both p110alpha and p110delta isoforms; membrane-resident HRas, not soluble HRas, increases membrane recruitment of both p110alpha and p110delta. (HRas = v-Ha-ras Harvey rat sarcoma viral oncogene homolog; p110alpha = class IA phosphoinositide 3-kinases, subunit p110alpha; p110delta = class IA phosphoinositide 3-kinases, subunit p110delta)

  3. Our data suggest that testing for any RAS mutation is unlikely to change the clinical management of thyroid nodules that have indeterminate cytology

  4. Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS and RRAS2 to the RAS binding (RB) domain of binding proteins.

  5. Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types.

  6. 6 of 7 (86%) malignant ectomesenchymomas had HRAS mutations

  7. RAS-positive thyroid cancer most often demonstrates indolent sonographic features and more commonly associates with lower risk, "indeterminate" cytology.

  8. Studies indicate that the control of spatiotemporal RAS protein signalling show that activation kinetics and subcellular compartmentalisation are tightly coupled to the generation of specific biological outcomes.

  9. HRAS mutation is associated in children with delayed puberty and probably with precocious puberty.

  10. HRAS mutation is associated with salivary duct carcinoma.

Mouse (Murine) V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. pancreatic ductal cells, whereas exhibiting relative resistance to oncogenic Kras alone, can serve as an effective cell of origin for pancreatic ductal adenocarcinoma in the setting of gain-of-function mutations in p53 (show TP53 Proteins)

  2. In vivo treatment of the KRAS(G12D)-induced Langerhans cell histiocytosis -like mouse with the cholesterol-lowering drug atorvastatin ameliorated the pathology, implicating statins as potential therapeutics against a subset of pulmonary Langerhans cell histiocytosis.

  3. overactivation of Kras signaling in type II collagen (show COL2A1 Proteins)-positive, immature osteoprogenitor cells, but not in mature osteoblasts, substantially increases the number of their descendant stromal cells and mature osteoblasts, and subsequently increases bone mass.

  4. this study shows that retinoic acid stabilizes HRas protein during neurogenesis.

  5. demonstrate the tumor suppressor function of WT Kras in oncogenic Kras-induced leukemogenesis and elucidate its underlying cellular and signaling mechanisms.

  6. Modification of the tumor microenvironment in KRAS or c-MYC (show MYC Proteins)-induced ovarian cancer-associated peritonitis has been described.

  7. we provide genetic evidence that the wild-type H-Ras and K-Ras proteins are bioequivalent in spite of their different structural and biological properties

  8. loss of one allele of Hras increased the sensitivity of mice to this carcinogen, and this effect was further exacerbated by the loss of the second Hras allele. However, loss of one or both alleles of Nras (show NRAS Proteins) failed to alter tumor burden, either in the absence or presence of Hras, after exposure to urethane.

  9. H-ras isoform mediates protection against pressure overload-induced cardiac dysfunction in part through activation of AKT (show AKT1 Proteins)/PI3K signaling pathway.

  10. KRAS K104Q mutant exhibited defects in both guanine nucleotide exchange factors -mediated exchange and GTPase-activating proteins -mediated GTP hydrolysis, consistent with NMR-detected structural perturbations in localized regions of KRAS important for recognition of these regulatory proteins.

HRAS Protein Profile

Protein Summary

This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.

Alternative names and synonyms associated with HRAS

  • Harvey rat sarcoma viral oncogene homolog (hras)
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS)
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog a (hrasa)
  • neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)
  • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)
  • Harvey rat sarcoma viral oncogene homolog (HRAS)
  • Harvey rat sarcoma virus oncogene (Hras)
  • Harvey rat sarcoma virus oncogene 1 (Hras1)
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog (Hras)
  • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras)
  • AI929937 protein
  • C-BAS/HAS protein
  • c-H-ras protein
  • c-Ha-ras protein
  • C-HA-RAS1 protein
  • c-rasHa protein
  • CTLO protein
  • H-ras protein
  • H-RASIDX protein
  • Ha-ras protein
  • HAMSV protein
  • Harvey-ras protein
  • hras protein
  • Hras-1 protein
  • HRAS1 protein
  • K-ras protein
  • Ki-ras protein
  • Kras-2 protein
  • Kras2 protein
  • N-RAS protein
  • p21B protein
  • ras protein
  • RASH1 protein
  • zgc:110250 protein

Protein level used designations for HRAS

v-Ha-ras Harvey rat sarcoma viral oncogene homolog , small G-protein H-Ras , Harvey ras 1 , p19 H-RasIDX protein , GTPase HRas (Transforming protein p21) (H-Ras-1) (c-H-ras) , xRAS1 , GTPase HRas , Transforming protein p21 , neuroblastoma ras oncogene , GTP- and GDP-binding peptide B , H-Ras-1 , Ha-Ras1 proto-oncoprotein , Ras family small GTP binding protein H-Ras , c-has/bas p21 protein , c-ras-Ki-2 activated oncogene , p21ras , transformation gene: oncogene HAMSV , transforming protein p21 , Harvey ras1 protein , Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog , H-ras 1 protein , c-Ha-ras p21 protein , c-Ha-ras transgene , transforming protein P21 , GTPase NRas , transforming protein N-Ras , c-H-ras , v-Ha-ras Harvey rat sarcoma viral oncogene-like protein , ras p21 , GTPase KRas , K-Ras 2 , Kirsten rat sarcoma oncogene 2, expressed , c-K-ras , c-Ki-ras , p21 protein

GENE ID SPECIES
399406 Xenopus laevis
466302 Pan troglodytes
513012 Bos taurus
549757 Xenopus (Silurana) tropicalis
550286 Danio rerio
698830 Macaca mulatta
733587 Sus scrofa
100222058 Taeniopygia guttata
100227892 Taeniopygia guttata
3265 Homo sapiens
293621 Rattus norvegicus
15461 Mus musculus
100739349 Sus scrofa
100735038 Cavia porcellus
396229 Gallus gallus
403735 Canis lupus familiaris
100298939 Bos taurus
101104357 Ovis aries
16653 Mus musculus
Selected quality suppliers for HRAS Proteins (HRAS)
Did you look for something else?